1883650-95-0

Basic information

• Product Name: 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4-(pyridin-3-yl)-1H-imidazole
• CAS NO: 1883650-95-0
• Molecular Weight: 618.819
• Mol File: 1883650-95-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4-(pyridin-3-yl)-1H-imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4-(pyridin-3-yl)-1H-imidazole(1883650-95-0)
• EPA Substance Registry System: 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4-(pyridin-3-yl)-1H-imidazole(1883650-95-0)

Safety Data

• Hazardous Substances Data: 1883650-95-0(Hazardous Substances Data)

Usage

Chemical class

Triterpenoids

Parent compound

Oleanolic acid

Synthetic derivative

Yes

Pharmaceutical properties

Extensively studied

Biological activities

Anti-inflammatory, anti-cancer, and anti-oxidant

In vitro and in vivo studies

Exhibited activities

Preclinical trials

Showed promising results in inhibiting cancer cell growth and metastasis

Potential drug development

Candidate for new drugs to treat various diseases

Upstream product

• 51746-85-1 3-(1H-imidazol-4-yl)pyridine 
• 443104-14-1 2-cyano-3,12-dioxooleana-1,9⁽¹¹⁾-dien-28-oic acid chloride 
• 218600-44-3 bardoxolone 

Relevant articles and documents

Discovery of bardoxolone derivatives as novel orally active necroptosis inhibitors

Necroptosis is a form of programmed cell death that contributes to the pathophysiology of cerebral ischemia/reperfusion (I/R) injury. In this study, bardoxolone (CDDO, 7) was an inhibitor of necroptosis identified from an in-house natural product library. Further optimization led to identify a more potent analogue 20. Compound 20 could effectively protect against necroptosis in human and mouse cells. The antinecroptotic effect could also be synergized with other necroptosis inhibitors. It blocked necrosome formation by targeting Hsp90 to inhibit the phosphorylation of RIPK1 and RIPK3 in necroptotic cells. In vivo, this compound was orally active to alleviate TNF-induced systemic inflammatory response syndrome (SIRS) and cerebral I/R injury. Our results suggested that 20 could be a lead compound for discovering necroptosis inhibitors in I/R treatment.

Triterpenoid derivatives and application thereof as programmed cell death inhibitor

The invention discloses a triterpenoid derivative, or a prodrug of an isomer, salt or solvate of the triterpenoid derivative. The triterpenoid derivative has a general formula structure shown in a formula I, wherein substituent groups in the formula are shown in the specification in detail. The triterpenoid derivative or the isomer, salt or solvate prodrug thereof can be used as a programmed celldeath inhibitor to effectively inhibit programmed death of cells and can be used to prepare medicines for preventing and treating ischemic diseases related to programmed cell death.